ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,836.56
-0.36%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Synta Pharmaceuticals Corp. (MM) (SNTA)

  7. Synta Pharmaceuticals Corp. (MM) (SNTA) Noticias

SNTA

Synta Pharmaceuticals Corp. (MM) (SNTA)

Synta Pharmaceuticals Corp. (MM)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SNTA
FechaHoraFuenteTítuloSímboloCompañía
29/07/201614:13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
26/07/201616:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
26/07/201614:38Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
22/07/201616:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
22/07/201610:30GlobeNewswire Inc.Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH CompanyNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
21/07/201615:17Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
20/07/201615:04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/07/201615:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
01/07/201606:35PR Newswire (US)Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/06/201615:15Business WireSynta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal PharmaceuticalsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/06/201615:03Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/06/201606:00Business WireSynta Pharmaceuticals to Present at Upcoming Investor Conferences in JuneNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
27/05/201607:20PR Newswire (US)Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat BiologicsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
19/05/201605:03Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
29/04/201607:33Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
28/04/201605:12Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
14/04/201606:00Business WireSynta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH CompanyNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
13/11/201510:22Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
05/11/201516:20Business WireSynta Reports Third Quarter 2015 Financial ResultsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
20/10/201518:30Business WireSynta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung CancerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/10/201506:30Business WireSynta Pharmaceuticals Announces Formation of Expert Oncology PanelNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
09/09/201507:00Business WireSynta Names Alan C. Rigby, Ph.D. Chief Scientific OfficerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/09/201507:00Business WireSynta Announces Presentations at the 16th Annual World Conference on Lung CancerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/09/201515:01Business WireSynta to Participate in FBR Second Annual Healthcare ConferenceNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/08/201511:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/08/201506:00Business WireSynta Reports Second Quarter 2015 Financial ResultsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
30/07/201515:01Business WireSynta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
23/06/201507:00Business WireSynta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition & Immune Checkpoint Blockade for Ca...NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
16/06/201515:01Business WireSynta to Participate in Upcoming Investor ConferencesNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/06/201508:00Business WireSynta Announces Ganetespib Program UpdatesNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
 Showing the most relevant articles for your search:NASDAQ:SNTA

Su Consulta Reciente

AMEX
VGZ
Vista Gold
BIT
PABC
Amundi icpr Euro Corpora...
BIT
P133G1
BNP PARIBAS ISSUANCE
ASX
NABJOA
COIN
MTRAXUST
MTRAX
TSX
9149
Otomo Logistics Service
NASDAQ
NMSS
Nms Communications
LSE
VML
Vane Minerals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados